VANCOUVER, BC--(MARKET WIRE)--Sep 10, 2007 -- TapImmune Inc. (OTC BB:TPIM.OB - News) (Frankfurt:GX1A.F - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced FDA compliant testing company AppTec, headquartered in St. Paul, Minnesota, has begun preclinical testing of its lead product, a TAP-based therapeutic cancer vaccine. The immunotherapy vaccine is designed to treat a wide variety of TAP deficient carcinomas that include lung cancers, liver cancers, kidney cancers, head and neck cancers, breast cancers, melanomas, prostate cancers, colorectal cancers, and cervical cancers. This is the first step in the product development program that will bring the vaccine to Phase 1 Human studies.
